Riskpilot← Back to searchSign inGet full accessSandin Pharma Consulting AB
ABActiveOrg 5569427031Sankt Görans Gränd 7 AResearch and experimental development on natural sciences and engineering · NACE 7210Est. 20131 employees
Revenue 2024
SEK -1
-67% vs 2023
EBITDA margin
2643400.0%
-69% vs 2023
Equity ratio
48.1%
Financial strength
Net profit 2024
SEK -26K
-70% vs 2023
| Revenue | SEK -1 | -67% |
| EBITDA | SEK -26K | -69% |
| Net profit | SEK -26K | -70% |
| Total assets | SEK 53K | -32% |
| Equity | SEK 26K | -49% |
| Employees | 1 | — |
Legal name
Sandin Pharma Consulting AB
Org number
5569427031
Legal form
Aktiebolag
NACE code
7210 · Research and experimental development on natural sciences and engineering
Founded
17 september 2013
Share capital
SEK 50 000
Employees
1 (FTE)
VAT registered
Yes
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Signatory rights
Firman tecknas av styrelsen
Company purpose
Företaget skall bedriva personalbemanning, konsultverksamhet, forskning och utbildning inom det medicinska området. Bolaget ska också bedriva utbildning och konsultverksamhet inom området informationsteknologi och multimedia. Vidare skall företaget bedriva verksamhet inom området byggnadssnickeri och hantverkshjälp. Därutöver ska bolaget äga och förvalta fastigheter och värdepapper och därmed förenlig verksamhet.
Address
Sankt Görans Gränd 7 A
Email
jsandin70@gmail.com
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | −0 | −0 | −0 |
| Staff expenses | — | — | — | — | — |
| EBITDA | −32 | −31 | −27 | −16 | −26 |
| Depreciation & amort. | −0 | −0 | — | — | — |
| EBIT | −32 | −31 | −27 | −16 | −26 |
| Net financials | — | — | 0 | 0 | 1 |
| Profit before tax | −12 | −31 | −27 | −15 | −26 |
| Tax | −0 | −0 | — | — | — |
| Net profit | −12 | −31 | −27 | −15 | −26 |
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Total assets | 123 | 94 | 92 | 78 | 53 |
| Equity | 83 | 67 | 64 | 50 | 26 |
| Long-term debt | 0 | 0 | — | — | — |
| Short-term debt | 41 | 28 | 28 | 28 | 28 |
| Total debt | 41 | 28 | 28 | 28 | 28 |
EBITDA margin
-2643400.0%
This company
15.8%
Market median
-16730480% vs market
20202024
Equity ratio
48.1%
This company
38.2%
Market median
+26% vs market
20202024
Return on equity
-101.0%
This company
18.4%
Market median
-649% vs market
20202024
Net profit margin
-2578000.0%
This company
8.1%
Market median
-31827260% vs market
20202024
Asset turnover
-0.00×
This company
1.12×
Market median
-100% vs market
20202024
Debt / equity
1.08×
This company
0.62×
Market median
-74% vs market
20202024
- Annual report 2024Filed via Bolagsverket / SCB · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Bolagsverket / SCB · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Bolagsverket / SCB · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Bolagsverket / SCB · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via Bolagsverket / SCB · Period 2020-01-01 – 2020-12-31
| Name | Role | Member since |
|---|---|---|
| Current (1) | ||
SJ Chief Executive Officer | Chief Executive Officer | 2022 |
| Name | Role | Member since |
|---|---|---|
| Current (1) | ||
| Deputy Board Member | 2022 | |
No shareholder data available.
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of Sandin Pharma Consulting AB also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Sven Johan Bertil Edvin Sandin | Chief Executive Officer | 0 companies |
| Annakarin Melcherson | Deputy Board Member | 0 companies |